Skip to contentS
Sunshine Biopharma Inc.
S
SBFMSunshine Biopharma Inc. Q2 2025 · 10-Q
Revenue$9.41M$9.41M+1.2% vs Q2 2024 Net Income-$1.77M-$1.77MN/M vs Q2 2024 EPS Diluted-$0.82-$0.82N/M vs Q2 2024 Gross Profit$3,422,866+45.3% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sunshine Biopharma Inc. · CIK 1402328 · Engraved from SEC EDGAR
Operating Cash Flowderived-$1,273,398N/M Free Cash Flowderived-$1,433,398N/M Margins · derivedGross margin36.4%+11.0 pt vs Q2 2024
Operating margin-21.8%−8.2 pt vs Q2 2024
Net margin-18.8%−13.5 pt vs Q2 2024
ended Jun 30, 2025 · filed Aug 12, 2025 · 43 d after period end